Ticker News
$WALD News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
WALD director's fund buys 335,000 Class A shares at $1.5094
WALD filed SEC Form 4. After the transaction the fund beneficially owned 12,587,580 shares (indirect); Souza states he is the controlling shareholder of the fund's manager and disclaims direct beneficial ownership except for pecuniary interest.
FDA approves Obagi saypha ChIQ hyaluronic-acid filler for cheek augmentation
Waldencast (WALD) announced FDA approval of Obagi saypha ChIQ, a hyaluronic-acid injectable indicated for cheek augmentation and correction of midface contour deficiencies in adults 21+. The product, developed with Croma‐Pharma using proprietary MACRO Core Technology, expands Obagi Medical's injectable portfolio and could boost cross‐sell into Obagi skincare following strong provider feedback from the recent saypha MagIQ launch; the company did not disclose launch timing, pricing, or pivotal clinical data for ChIQ.
Waldencast to sell Obagi Medical to Bridgepoint for up to $460M
Waldencast (WALD) agreed to sell 100% of Obagi Medical to Bridgepoint for an enterprise value of up to $460 million, with closing expected in Q3 2026 subject to customary regulatory approvals and purchase-price adjustments. The company intends to use proceeds to repay about $178 million of senior secured term debt and refocus on growing Milk Makeup, while founders Michel Brousset and Hind Sebti will transition to lead Obagi with Bridgepoint.